These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 4072227)
1. [Platelet function after the single administration of buflomedil]. Sinzinger H; Wirthumer-Hoche C Wien Klin Wochenschr; 1985 Sep; 97(18):720-2. PubMed ID: 4072227 [TBL] [Abstract][Full Text] [Related]
2. Effect of buflomedil on epinephrine-enhanced platelet aggregation in vitro and ex vivo. Wurzinger LJ; Schmid-Schönbein H Arzneimittelforschung; 1987 Oct; 37(10):1113-5. PubMed ID: 3435582 [TBL] [Abstract][Full Text] [Related]
3. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. Diamantopoulos EJ; Grigoriadou M; Ifanti G; Raptis SA Int Angiol; 2001 Dec; 20(4):337-44. PubMed ID: 11782701 [TBL] [Abstract][Full Text] [Related]
4. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation. Siess W; Roth P; Weber PC Thromb Haemost; 1981 Jun; 45(3):204-7. PubMed ID: 7025338 [TBL] [Abstract][Full Text] [Related]
5. Effect of buflomedil on in vitro prostacyclin and endothelin synthesis by vascular (rat and human) and penile (rat) tissue and calcium uptake by isolated human platelets. Jeremy JY; Gill J; DuBourg A; Pelat P; Mikhailidis DP Int J Impot Res; 1993 Sep; 5(3):139-47. PubMed ID: 8124432 [TBL] [Abstract][Full Text] [Related]
6. Levosimendan has an inhibitory effect on platelet function. Kaptan K; Erinç K; Ifran A; Yildirim V; Uzun M; Beyan C; Işik E Am J Hematol; 2008 Jan; 83(1):46-9. PubMed ID: 17654687 [TBL] [Abstract][Full Text] [Related]
7. Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug interaction on platelet function. Cerletti C; Bonati M; del Maschio A; Galletti F; Dejana E; Tognoni G; de Gaetano G J Lab Clin Med; 1984 Jun; 103(6):869-77. PubMed ID: 6726057 [TBL] [Abstract][Full Text] [Related]
8. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542 [TBL] [Abstract][Full Text] [Related]
9. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Pampuch A; Cerletti C; de Gaetano G Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371 [TBL] [Abstract][Full Text] [Related]
10. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Heptinstall S; May JA; Glenn JR; Sanderson HM; Dickinson JP; Wilcox RG Thromb Haemost; 1995 Nov; 74(5):1310-5. PubMed ID: 8607115 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo effects of desmopressin on platelet function. Balduini CL; Noris P; Belletti S; Spedini P; Gamba G Haematologica; 1999 Oct; 84(10):891-6. PubMed ID: 10509036 [TBL] [Abstract][Full Text] [Related]
13. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899 [TBL] [Abstract][Full Text] [Related]
14. In vitro studies of the effect of buflomedil on platelet responsiveness. Ryckewaert JJ; Maurel A; Marguerie G Haemostasis; 1990; 20(3):181-91. PubMed ID: 1974871 [TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of ticlopidine: relation between dose and time of administration to platelet inhibition. Kuzniar J; Splawinska B; Malinga K; Mazurek AP; Splawinski J Int J Clin Pharmacol Ther; 1996 Aug; 34(8):357-61. PubMed ID: 8864800 [TBL] [Abstract][Full Text] [Related]
16. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms underlying increased platelet reactivity in patients with peripheral arterial disease. Preliminary results. Reininger CB; Boeger CA; Steckmeier B; Spannagl M; Scweiberer L Int Angiol; 1999 Jun; 18(2):163-70. PubMed ID: 10424375 [TBL] [Abstract][Full Text] [Related]
19. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Blais N; Pharand C; Lordkipanidzé M; Sia YK; Merhi Y; Diodati JG Thromb Haemost; 2009 Aug; 102(2):404-11. PubMed ID: 19652893 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]